Gorham-Stout case report: a multi-omic analysis reveals recurrent fusions as new potential drivers of the disease.
AKT
Autophagy
Case report
Fusions
Genomics
Gorham-Stout
Mutations
PI3K
Transcriptomics
mTOR
Journal
BMC medical genomics
ISSN: 1755-8794
Titre abrégé: BMC Med Genomics
Pays: England
ID NLM: 101319628
Informations de publication
Date de publication:
06 06 2022
06 06 2022
Historique:
received:
25
02
2022
accepted:
23
05
2022
entrez:
6
6
2022
pubmed:
7
6
2022
medline:
9
6
2022
Statut:
epublish
Résumé
Gorham-Stout disease is a rare condition characterized by vascular proliferation and the massive destruction of bone tissue. With less than 400 cases in the literature of Gorham-Stout syndrome, we performed a unique study combining whole-genome sequencing and RNA-Seq to probe the genomic features and differentially expressed pathways of a presented case, revealing new possible drivers and biomarkers of the disease. We present a case report of a white 45-year-old female patient with marked bone loss of the left humerus associated with vascular proliferation, diagnosed with Gorham-Stout disease. The analysis of whole-genome sequencing showed a dominance of large structural DNA rearrangements. Particularly, rearrangements in chromosomes seven, twelve, and twenty could contribute to the development of the disease, especially a gene fusion involving ATG101 that could affect macroautophagy. The study of RNA-sequencing data from the patient uncovered the PI3K/AKT/mTOR pathway as the most affected signaling cascade in the Gorham-Stout lesional tissue. Furthermore, M2 macrophage infiltration was detected using immunohistochemical staining and confirmed by deconvolution of the RNA-seq expression data. The way that DNA and RNA aberrations lead to Gorham-Stout disease is poorly understood due to the limited number of studies focusing on this rare disease. Our study provides the first glimpse into this facet of the disease, exposing new possible therapeutic targets and facilitating the clinicopathological diagnosis of Gorham-Stout disease.
Sections du résumé
BACKGROUND
Gorham-Stout disease is a rare condition characterized by vascular proliferation and the massive destruction of bone tissue. With less than 400 cases in the literature of Gorham-Stout syndrome, we performed a unique study combining whole-genome sequencing and RNA-Seq to probe the genomic features and differentially expressed pathways of a presented case, revealing new possible drivers and biomarkers of the disease.
CASE PRESENTATION
We present a case report of a white 45-year-old female patient with marked bone loss of the left humerus associated with vascular proliferation, diagnosed with Gorham-Stout disease. The analysis of whole-genome sequencing showed a dominance of large structural DNA rearrangements. Particularly, rearrangements in chromosomes seven, twelve, and twenty could contribute to the development of the disease, especially a gene fusion involving ATG101 that could affect macroautophagy. The study of RNA-sequencing data from the patient uncovered the PI3K/AKT/mTOR pathway as the most affected signaling cascade in the Gorham-Stout lesional tissue. Furthermore, M2 macrophage infiltration was detected using immunohistochemical staining and confirmed by deconvolution of the RNA-seq expression data.
CONCLUSIONS
The way that DNA and RNA aberrations lead to Gorham-Stout disease is poorly understood due to the limited number of studies focusing on this rare disease. Our study provides the first glimpse into this facet of the disease, exposing new possible therapeutic targets and facilitating the clinicopathological diagnosis of Gorham-Stout disease.
Identifiants
pubmed: 35668402
doi: 10.1186/s12920-022-01277-x
pii: 10.1186/s12920-022-01277-x
pmc: PMC9169400
doi:
Substances chimiques
RNA
63231-63-0
Types de publication
Case Reports
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
128Informations de copyright
© 2022. The Author(s).
Références
Nat Genet. 2000 Jan;24(1):45-8
pubmed: 10615125
J Pediatr Hematol Oncol. 2015 Nov;37(8):e481-5
pubmed: 26458155
Annu Rev Pathol. 2009;4:127-50
pubmed: 18767981
J Bone Miner Res. 2005 Feb;20(2):350-3
pubmed: 15647829
Cancer Cell. 2019 Mar 18;35(3):441-456.e8
pubmed: 30889380
Front Genet. 2020 Jul 03;11:605
pubmed: 32719714
Mol Cancer Res. 2003 Dec;1(14):1001-8
pubmed: 14707283
J Bone Oncol. 2015 May 16;4(2):42-6
pubmed: 26579487
Front Genet. 2019 Jan 23;9:727
pubmed: 30733730
Skelet Muscle. 2017 Jul 11;7(1):15
pubmed: 28697784
Hypertension. 2018 Feb;71(2):e1-e8
pubmed: 29279311
Oncogene. 2008 Sep 18;27(41):5527-41
pubmed: 18794886
J Hum Genet. 2020 Nov;65(11):995-1001
pubmed: 32591603
Autophagy. 2009 Oct;5(7):973-9
pubmed: 19597335
Clin Med Res. 2005 May;3(2):65-74
pubmed: 16012123
Pediatr Blood Cancer. 2016 May;63(5):931-4
pubmed: 26713883
J Bone Miner Res. 2006 Feb;21(2):207-18
pubmed: 16418776
Anat Rec (Hoboken). 2014 Sep;297(9):1694-705
pubmed: 25125182
J Hum Genet. 2016 Jan;61(1):33-9
pubmed: 26446362
J Exp Med. 2008 Jun 9;205(6):1255-9
pubmed: 18519650
Oncotarget. 2015 Jun 30;6(18):15842-56
pubmed: 26158294
Front Oncol. 2019 Oct 18;9:1088
pubmed: 31681616
Sci Rep. 2017 Dec 4;7(1):16878
pubmed: 29203879
Life Sci Alliance. 2021 Oct 13;4(12):
pubmed: 34645618
Nat Rev Cancer. 2003 Feb;3(2):102-9
pubmed: 12563309
J Surg Orthop Adv. 2010 Summer;19(2):85-90
pubmed: 20727303
Histopathology. 2020 Jul;77(1):79-91
pubmed: 32281132
Biomed Res Int. 2014;2014:670842
pubmed: 25530967
Semin Intervent Radiol. 2017 Sep;34(3):233-238
pubmed: 28955112
Genet Med. 2015 May;17(5):405-24
pubmed: 25741868
Autophagy. 2009 Jul;5(5):649-62
pubmed: 19287211
JCI Insight. 2021 Aug 9;6(15):
pubmed: 34156985
J Pediatr. 2015 Apr;166(4):1048-54.e1-5
pubmed: 25681199
Curr Opin Genet Dev. 2002 Jun;12(3):349-61
pubmed: 12076680
Am J Med Genet A. 2012 Jul;158A(7):1719-23
pubmed: 22628360
Clin Cancer Res. 2008 Sep 1;14(17):5318-24
pubmed: 18765522
Orthop Surg. 2018 Aug;10(3):276-280
pubmed: 30101546
J Bone Joint Surg Am. 1955 Oct;37-A(5):985-1004
pubmed: 13263344
Adv Wound Care (New Rochelle). 2019 Jun 1;8(6):230-245
pubmed: 31236308
Oxid Med Cell Longev. 2021 Jun 20;2021:5546711
pubmed: 34239689
BMC Musculoskelet Disord. 2019 Dec 31;21(1):3
pubmed: 31892358
Signal Transduct Target Ther. 2017;2:
pubmed: 29158945
BMC Musculoskelet Disord. 2020 Aug 25;21(1):577
pubmed: 32843029
Front Mol Neurosci. 2011 Dec 02;4:51
pubmed: 22144946